arrow
M

Marc S. Ernstoff

dartmouth hitchcock medical center
H指数:80
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated differential transcript usage and transcript abundance analyses reveal isoform-level remodeling in clear cell renal cell carcinoma

整合差异转录本使用和转录本丰度分析揭示了透明细胞肾细胞癌中的异构体水平重塑

2026-10-110
OAAI
A phase II pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma, with sequential evaluation of the tumor microenvironment

晚期黑色素瘤患者中吲哚胺2,3-双加氧酶-1(IDO1)抑制剂(INCB024360)联合多肽黑色素瘤疫苗(MELITAC 12.1)的II期初步试验,并序贯评估肿瘤微环境

2026-10-020
OAAI
Chronic sequelae of immune-related adverse events

免疫相关不良事件的慢性后遗症

2026-03-040
PRE
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

Monson, K.R.; Ferguson, R.; Handzlik, J.E.; Morales, L.; Xiong, J.; Chat, V.; Dagayev, S.; Khodadadi-Jamayran, A.; Simpson, D.; Kazlow, E.; 等. 继承的线粒体遗传学作为预测黑色素瘤免疫检查点抑制疗效的指标。Nat. Med. 2025, 31, 2385–2396. [Google Scholar] [CrossRef]

2025-06-050
OAAI
Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
2023-10-010
OA
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

黑色素瘤的观点: 黑色素瘤桥会议报告 (2022年12月1至3日-意大利那不勒斯)

2023-07-282
OAAI
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

最大限度地提高免疫肿瘤学III期试验的价值: 癌症免疫疗法协会 (SITC) 的清单

2022-09-298
OAAI
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd-4th, 2021, Italy)

黑色素瘤的观点: 黑色素瘤桥会议报告 (意大利2021年12月2至4日)

2022-09-042
OAAI
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study
2022-08-1211
OAAI
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
2022-08-036
OAAI
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
2021-11-1769
OAAI